Commitments and Contingencies	6 Months Ended
Jun. 30, 2026
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Regulatory Matter With the assistance of outside counsel, the Company voluntarily conducted an internal investigation that focused on the compliance of certain consulting and service agreements with federal healthcare laws and regulations, including those relating to fraud, waste and abuse. Based on this internal investigation, the Company voluntarily notified the Office of Inspector General of the U.S. Department of Health and Human Services (“OIG”) of the Company’s internal investigation in November 2021, and thereafter cooperated with the government's investigation of this matter. As previously disclosed, on July 20, 2026, the Company entered into a civil settlement agreement (the “Settlement Agreement”) with the U.S. Department of Justice (“DOJ”), on behalf of the OIG, resolving the government's investigation concerning consulting services provided by the Company to certain health care providers for laboratory testing services as part of its Laboratory Clinical Initiative program. Under the terms of the Settlement Agreement, the Company agreed to pay the United States $10.0 million, consisting of a settlement amount of approximately $9.8 million plus accrued interest of $0.2 million, payable within 15 days of July 20, 2026. The Settlement Agreement resolves the DOJ's investigation of this matter, does not require the Company to enter into a corporate integrity agreement or undertake other ongoing compliance obligations, and is neither an admission of liability by the Company nor a concession by the United States that its claims are not well founded. The Settlement Agreement was executed subsequent to June 30, 2026 and prior to the issuance of the accompanying consolidated financial statements, and provided additional evidence about conditions that existed as of the balance sheet date. Accordingly, the Company adjusted its previously established reserve for this matter to the final settlement amount as of June 30, 2026, and recognized a benefit of approximately $1.2 million in general and administrative expenses in the Consolidated Statements of Operations for the three and six months ended June 30, 2026, representing the difference between the $11.2 million previously reserved and the final settlement amount. As of June 30, 2026, the resulting liability of $10.0 million is recorded within accrued expenses and other current liabilities on the Consolidated Balance Sheets, reflecting expected payment in the third quarter of 2026. As of December 31, 2025, the reserve of $11.2 million was recorded in other long-term liabilities on the Consolidated Balance Sheets. Legal Proceedings On December 16, 2022, a purported shareholder class action captioned Daniel Goldenberg v. NeoGenomics, Inc., Douglas VanOort, Mark Mallon, Kathryn McKenzie, and William Bonello was filed in the United States District Court for the Southern District of New York, naming the Company and certain of the Company’s current and former officers as defendants (“the Goldenberg Matter”). This lawsuit was filed by a stockholder who claims to be suing on behalf of anyone who purchased or otherwise acquired the Company’s securities between February 27, 2020 and April 26, 2022. The lawsuit alleges that material misrepresentations and/or omissions of material fact were made in the Company’s public disclosures in violation of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder. The alleged improper disclosures relate to statements regarding the Company’s menu of tests, business operations and compliance with health care laws and regulations. The Company filed a motion to dismiss the Goldenberg Matter on February 5, 2024 and the plaintiff filed its opposition to the motion on March 21, 2024. On March 13, 2026, the Court entered a Memorandum and Order dismissing the Goldenberg Matter with prejudice. On April 10, 2026, the plaintiff appealed the judgment and order to the United States Court of Appeals for the Second Circuit. The plaintiff seeks unspecified monetary damages on behalf of the putative class and an award of costs and expenses, including attorney’s fees and expert fees. On April 27, 2023, a shareholder of the Company filed a shareholder derivative action on behalf of the Company captioned Puskarich v. VanOort, et al. in Clark County Nevada, naming certain of the Company’s current and former officers and directors as defendants. The allegations are substantially similar to the allegations asserted in the Goldenberg Matter. Substantially similar shareholder derivative actions were subsequently filed in Lee County, Florida and in the United States District Court for the Southern District of New York, captioned Wong v. VanOort, et al. and Mellema v. VanOort, et al., respectively. Proceedings in the shareholder derivative actions are currently stayed pending resolution of the appeal in the Goldenberg matter. The Company believes that it has valid defenses to the claims alleged in the lawsuits, but there is no guarantee that the Company will prevail. As of the filing of this report with the SEC, the outcome of these matters is not estimable or probable.

With the assistance of outside counsel, the Company voluntarily conducted an internal investigation that focused on the compliance of certain consulting and service agreements with federal healthcare laws and regulations, including those relating to fraud, waste and abuse. Based on this internal investigation, the Company voluntarily notified the Office of Inspector General of the U.S. Department of Health and Human Services (“OIG”) of the Company’s internal investigation in November 2021, and thereafter cooperated with the government's investigation of this matter.

As previously disclosed, on July 20, 2026, the Company entered into a civil settlement agreement (the “Settlement Agreement”) with the U.S. Department of Justice (“DOJ”), on behalf of the OIG, resolving the government's investigation concerning consulting services provided by the Company to certain health care providers for laboratory testing services as part of its Laboratory Clinical Initiative program. Under the terms of the Settlement Agreement, the Company agreed to pay the United States $10.0 million, consisting of a settlement amount of approximately $9.8 million plus accrued interest of $0.2 million, payable within 15 days of July 20, 2026. The Settlement Agreement resolves the DOJ's investigation of this matter, does not require the Company to enter into a corporate integrity agreement or undertake other ongoing compliance obligations, and is neither an admission of liability by the Company nor a concession by the United States that its claims are not well founded.

The Settlement Agreement was executed subsequent to June 30, 2026 and prior to the issuance of the accompanying consolidated financial statements, and provided additional evidence about conditions that existed as of the balance sheet date. Accordingly, the Company adjusted its previously established reserve for this matter to the final settlement amount as of June 30, 2026, and recognized a benefit of approximately $1.2 million in general and administrative expenses in the Consolidated Statements of Operations for the three and six months ended June 30, 2026, representing the difference between the $11.2 million previously reserved and the final settlement amount. As of June 30, 2026, the resulting liability of $10.0 million is recorded within accrued expenses and other current liabilities on the Consolidated Balance Sheets, reflecting expected payment in the third quarter of 2026. As of December 31, 2025, the reserve of $11.2 million was recorded in other long-term liabilities on the Consolidated Balance Sheets.

On December 16, 2022, a purported shareholder class action captioned Daniel Goldenberg v. NeoGenomics, Inc., Douglas VanOort, Mark Mallon, Kathryn McKenzie, and William Bonello was filed in the United States District Court for the Southern District of New York, naming the Company and certain of the Company’s current and former officers as defendants (“the Goldenberg Matter”). This lawsuit was filed by a stockholder who claims to be suing on behalf of anyone who purchased or otherwise acquired the Company’s securities between February 27, 2020 and April 26, 2022. The lawsuit alleges that material misrepresentations and/or omissions of material fact were made in the Company’s public disclosures in violation of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder. The alleged improper disclosures relate to statements regarding the Company’s menu of tests, business operations and compliance with health care laws and regulations. The Company filed a motion to dismiss the Goldenberg Matter on February 5, 2024 and the plaintiff filed its opposition to the motion on March 21, 2024. On March 13, 2026, the Court entered a Memorandum and Order dismissing the Goldenberg Matter with prejudice. On April 10, 2026, the plaintiff appealed the judgment and order to the United States Court of Appeals for the Second Circuit. The plaintiff seeks unspecified monetary damages on behalf of the putative class and an award of costs and expenses, including attorney’s fees and expert fees. On April 27, 2023, a shareholder of the Company filed a shareholder derivative action on behalf of the Company captioned Puskarich v. VanOort, et al. in Clark County Nevada, naming certain of the Company’s current and former officers and directors as defendants. The allegations are substantially similar to the allegations asserted in the Goldenberg Matter. Substantially similar shareholder derivative actions were subsequently filed in Lee County, Florida and in the United States District Court for the Southern District of New York, captioned Wong v. VanOort, et al. and Mellema v. VanOort, et al., respectively. Proceedings in the shareholder derivative actions are currently stayed pending resolution of the appeal in the Goldenberg matter. The Company believes that it has valid defenses to the claims alleged in the lawsuits, but there is no guarantee that the Company will prevail. As of the filing of this report with the SEC, the outcome of these matters is not estimable or probable.